[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aphthous-ulcer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aphthous-ulcer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100639225","observational-study-of-orosedal-in-sore-throat-and-minor-oral-lesions-100639225",false,"NCT07620353","Observational Study of OROSEDAL in Sore Throat and Minor Oral Lesions","Relief of Sore Throat Pain or Minor Mouth Lesions, Including Minor Aphthous Ulcers, in Children and Adults Treated With OROSEDAL: An Observational Study","Inclusion Criteria:\n\n* Age 8 years or older, including adults.\n* Sore throat or minor mouth lesion, including minor aphthous ulcer or histologically confirmed oral lichen planus, evolving for less than 15 days.\n* Global pain intensity over the previous 24 hours, spontaneous and\u002For during chewing or swallowing, \\>40 mm on a 0-100 mm visual analog scale.\n* OROSEDAL prescription decided by the investigator before inclusion.\n* Written informed consent from the patient or from one parent for minors.\n\nExclusion Criteria:\n\n* More than 3 visible oral mucosal lesions.\n* Post-intubation sore throat.\n* Corticosteroid use ongoing or within 3 days before inclusion.\n* NSAID use ongoing or within 3 days before inclusion.\n* Local treatment on the lesion ongoing or within 3 days before inclusion.\n* Non-opioid analgesics, including paracetamol, ongoing or within 3 days before inclusion, unless continued for at least 24 hours at the same daily dose as during the 24 hours before inclusion.\n* Weak or strong opioid analgesics ongoing or within 3 days before inclusion.\n* Signs suggesting a condition requiring additional investigations according to the investigator, except rapid streptococcal throat testing.\n* Signs suggesting a condition requiring corticosteroid prescription according to the investigator.\n* Systemic disease, such as rheumatoid arthritis, lupus, or Behçet disease.\n* Any contraindication listed in OROSEDAL instructions for use.\n* Known allergy to any OROSEDAL component, including glycerol, tamarind extract, mallow extract, benzyl alcohol, orange blossom flavoring, or xylitol.\n* Non-compliance with precautions for use listed in the instructions for use.","ALL","8 Years",{"count":19,"type":20},124,"ESTIMATED","OBSERVATIONAL","This prospective, multicenter, national, observational, non-interventional post-market clinical follow-up study will evaluate the performance and safety of OROSEDAL in children and adults with sore throat or minor oral lesions, including minor aphthous ulcers and histologically confirmed oral lichen planus. OROSEDAL is prescribed in routine practice before inclusion. Patients will be followed for 6 ± 1 days and will complete self-assessments of pain, swallowing discomfort, treatment use, and adverse events.",[24,25,26,27,28],"Sore Throat","Aphthous Ulcer","Oral Lichen Planus","Minor Mouth Lesion","Oral Pain",[30,31,32,33,34,35,36],"sore throat","aphthous ulcer","mouth ulcer","oral lesion","PMCF","real-world evidence","swallowing discomfort","RECRUITING","2026-05-27",{"date":40,"type":41},"2026-06-02","ACTUAL",{"date":43,"type":41},"2026-03-05",{"date":45,"type":20},"2027-07",{"name":47,"class":48},"Laboratoires Elerte","INDUSTRY",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":49},"100603841","salivary-e-cadherin-calprotectin-and-matrix-metalloproteinase-9-levels-in-recurrent-aphthous-stomatitis-100603841","NCT07141758","Salivary E-cadherin, Calprotectin, and Matrix Metalloproteinase-9 Levels in Recurrent Aphthous Stomatitis","Investigation of Salivary E-cadherin, Calprotectin, and Matrix Metalloproteinase-9 Levels in Patients With Recurrent Aphthous Stomatitis","Inclusion Criteria:\n\n* Participants aged 18 years or older\n* Clinically diagnosed with minor recurrent aphthous stomatitis (RAS) (defined as having a history of at least three RAS episodes within the past year)\n* Systemically healthy (i.e., without any diagnosed systemic disease)\n* No history of tobacco use\n* Presence of at least one active aphthous ulcer at the time of saliva sample collection\n* No known mental or physical disabilities\n\nExclusion Criteria:\n\n* Use of any pharmacological treatment within the past 3 months\n* Use of antiseptic mouthwash within the past 3 months\n* Pregnant or lactating individuals, or those currently using oral contraceptives\n* History of systemic diseases associated with oral ulcerations such as Crohn's disease, ulcerative colitis, celiac disease, or Behçet's disease\n* History of chemotherapy or radiotherapy\n* Current or prior use of immunomodulatory drugs, cytotoxic agents, or systemic corticosteroids\n* Undergoing orthodontic treatment (to avoid misdiagnosis with traumatic ulcers)\n* Use of removable dental prostheses (to avoid misdiagnosis with traumatic ulcers)\n* Presence of periodontal disease (CPI score of 3 or 4)\n* Caries risk not classified as very low (DMFT ≥ 5)\n* Presence of pathological oral mucosal lesions such as lichen planus, pemphigus vulgaris, or mucous membrane pemphigoid",true,"18 Years",{"count":60,"type":20},102,"The goal of this observational cross-sectional study is to determine the salivary levels of E-cadherin, Calprotectin, and Matrix Metalloproteinase-9 (MMP-9) in patients with Recurrent Aphthous Stomatitis (RAS) and to compare them with those of healthy controls.\n\nThe main questions it aims to answer are:\n\nAre the salivary levels of E-cadherin, Calprotectin, and MMP-9 significantly different in patients with minor RAS compared to healthy controls?\n\nCan these salivary proteins serve as biomarkers involved in the pathogenesis of minor RAS?\n\nResearchers will compare patients with minor RAS and healthy individuals to determine whether differences in salivary E-cadherin, Calprotectin, and MMP-9 levels are associated with the presence of disease.\n\nParticipants will:\n\nProvide unstimulated saliva samples using a saliva swab\n\nUndergo clinical evaluation for periodontal status (Community Periodontal Index - CPI) and caries experience (DMFT index)\n\nCollected saliva samples will be stored at -80°C until analysis. The concentrations of the investigated proteins will be measured using ELISA kits, and total protein levels will be determined using a colorimetric protein assay.\n\nThe relationships among the salivary concentrations of the investigated proteins, as well as their associations with demographic variables such as age and sex, will be analyzed.",[63,25],"Recurrent Aphthous Stomatitis",[65,66,67,68,69,70,71,72],"E-cadherin","Calprotectin","MMP-9","ELISA","Recurrent aphthous stomatitis","RAS","Saliva","Salivary Biomarkers","2025-08-25",{"date":75,"type":41},"2025-08-26",{"date":77,"type":41},"2025-04-10",{"date":79,"type":20},"2026-06-30",{"name":81,"class":82},"Selin Yeşiltepe","OTHER",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":49},"100579033","phase-4-effects-of-photobiomodulation-pbm-on-pain-after-presentation-of-aphthous-ulcers-in-pediatric-dental-patients-100579033","NCT06819033","Effects of Photobiomodulation (PBM) on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients","Effects of Photobiomodulation on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients","Inclusion Criteria:\n\n* Patient\u002Fguardian speaks either English or Spanish\n* Patient presenting with one or more aphthous ulcers in their mouth, identified during a scheduled dental appointment\n* No previous PBM treatment to the presenting aphthous ulcer(s)\n* Guardian able to partake in a follow-up phone call in either the English or Spanish language\n\nExclusion Criteria:\n\n* Patient presents with aphthous ulcers recently treated with PBM\n* Patient presents with herpes labialis (cold sores)\n* Patients presents with systemic disease that affects soft tissue\u002Fmucous healing","5 Years","17 Years",{"count":93,"type":20},30,"INTERVENTIONAL",[96],"PHASE4","The purpose of this study is to compare the efficacy of laser photobiomodulation and \"Magic Mouthwash\" for treatment of pain in pediatric patients with aphthous ulcers , to assess how photobiomodulation influences the rate of healing of aphthous ulcers in pediatric patients and to measure changes in pain levels reported by pediatric patients undergoing photobiomodulation treatment for aphthous ulcers.",[25],[100,101],"magic mouthwash","laser treatment","2025-03-20",{"date":104,"type":41},"2025-03-25",{"date":106,"type":41},"2025-03-10",{"date":108,"type":20},"2026-02-28",{"name":110,"class":82},"The University of Texas Health Science Center, Houston"]